Indomethacin is used to reduce pain, fever, and inflammation caused by conditions like arthritis, gout, and other inflammatory diseases. It can also be used to close a patent ductus arteriosus (a heart condition in newborns).[2] Indocin is currently approved and in use across 34 indications[4].[1]
Indocin is one of 559 small molecule programs targeting Patent ductus arteriosus after premature birth. It is currently in Approved.
Indications
Total Trials
Active Trials
Competitors
FDA Applications
NDA/BLA/ANDA regulatory filings
Patents
Pipeline
Competition
181 competitors in Rheumatoid Arthritis
Indocin
Actos
Celexa
Voltaren
Cataflam
Plaquenil
Vibramycin
Velcade
Vancocin
Disalcid
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Clinical
Regulatory
Jan 1, 1982
INDOCIN
NDA NDA016059
Feb 23, 1982
INDOCIN SR
NDA NDA018185
Apr 20, 1984
INDOMETHACIN
NDA NDA018858
May 4, 1984
INDOMETHACIN
NDA NDA018730
May 18, 1984
INDOMETHACIN
NDA NDA018851
Jul 31, 1984
INDOMETHACIN
NDA NDA018690
Aug 6, 1984
INDOMETHACIN
NDA NDA018829
Aug 13, 1984
INDOCIN
NDA NDA017814
Nov 23, 1984
INDOMETHACIN
NDA NDA018806
Jan 30, 1985
INDOCIN
NDA NDA018878
Oct 10, 1985
INDOCIN
NDA NDA018332
Mar 17, 2010
INDOMETHACIN
NDA NDA022536
Feb 24, 2014
TIVORBEX
NDA NDA204768
Sources
Details